🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Our paper on aza + ven +gilteritinib for FLT3mut #AML now online at Journal of Clinical Oncology In frontline FLT3mut AML, CR 90% (vs. 30-50% with aza+ven) and 18mo OS 72% (vs. 2yr OS 20-40% with aza+ven) Could be delivered safely with appropriate dose modifications. ascopubs.org/doi/10.1200/JC…

Someone used DALL-E to create gobbledygook scientific figures and submitted them to Frontiers Journal. And guess what? The editor published it. LOL frontiersin.org/articles/10.33…

FDA granted accelerated approval to ponatinib with chemotherapy for adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. fda.gov/drugs/resource… #OCENewsBurst

A very nice paper in Blood Journal elucidating the mechanisms of resistance to inotuzumab in B-ALL that go beyond loss of CD22 ashpublications.org/blood/article/…

Many pts with Ph+ #ALL can be salvaged with INO, blina or CAR T-cells after ponatinib failure. Long-term remissions possible in some pts without alloSCT Nicholas Short MD MD Anderson Cancer Center #Leukemia pubmed.ncbi.nlm.nih.gov/38607091/ AmericanJournalofHematology #leusm

Listening to #NicholasShort from ⁦⁦MD Anderson Cancer Center⁩ talking about #inotuzumab in relapsed refractory Acute lymphoblastic leukemia! Delhi

Our new review on inotuzumab ozogamicin is now online. We cover the clinical development of INO, pivotal studies, and the novel uses of INO in B-ALL, including combination therapies and use in the frontline setting.

NGS MRD (clonoSEQ) is the most sensitive and specific MRD assay in Ph+ #ALL. Therapeutic decision-making should be based on NGS rather than PCR for BCR::ABL1 Nicholas Short MD of MD Anderson Cancer Center #Leukemia doi.org/10.1080/174740… #leusm

Happy to see our trial of DAC, venetoclax and ponatinib for advanced phase CML published in The Lancet Haematology. Response rate was 80%, allowing for bridge to alloSCT. Still a lot more work to be done in this rare disease. We have new TKI combo studies now open and enrolling.

MRD is highly prognostic in #AML and can inform SCT decisions or enrollment into MRD-directed clinical trials. MRD endpoints may also allow for accelerated drug approval in AML. New review by Nicholas Short MD and Richard Dillon in AmericanJournalofHematology doi.org/10.1002/ajh.27… #leusm

Save the Date! calliecoombs John P. Leonard, MD Rami komrokji @farrukhawan Nicholas Short MD Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Krina Patel @corinneShahmehdi @jmaakaron Curtis Lachowiez Register at louisville.edu/medicine/cme/e… UofL Brown Cancer Center UofL Health UofL Medicine UofL Med School University of Louisville

CONGRESS #ASH24 | PRESENTATION Roberta Santos Azevedo, MD Anderson Cancer Center discussed older age and TP53 mutations as predictors of myeloid neoplasm. Incidence of t-MN was highest in pts older than 60, and also higher with treatment intensity and TP53 mutation. t-MN risk was highest

CONGRESS #ASH24 | PRESENTATION Walid Macaron, MD MSc, MD Anderson Cancer Center and BCMHouston discussed achievement of MRD negativity and positive long-term outcomes in B-ALL. In pts with PH- B-ALL , 2-yr RFS was higher in pts who were MRD neg after cycle 1, vs those who were pos after cycle 1.

CONGRESS | #ASH24 | PRESENTATION Nicholas Short MD MD Anderson Cancer Center shares long-term findings from a study of patients with ND FLT3m AML treated with HMA+Ven+FLT3i triplet (N = 73). ▪️Efficacy overall was comparable to that seen with doublet therapy, and at median follow-up of 26

Very nice of AmericanJournalofHematology to add a wonderful visual abstract to accompany our review article on MRD in AML. Link here: onlinelibrary.wiley.com/doi/10.1002/aj… Richard Dillon

Early attainment of undetectable MRD by MFC is independently associated w/ improved RFS in newly diagnosed #AML. Intermediate risk pts who attain undetectable MRD should still undergo consolidative allo-SCT. MD Anderson Cancer Center #Leukemia ASH ashpublications.org/bloodadvances/…

Recommendations from a panel of US experts published in Blood Advances highlight the optimal use of MRD as a prognostic and therapeutic tool in adult ALL More news: loom.ly/EvtL7yw #ALLsm #leusm #MedNews #MedEd

Expert recommendations on using MRD in #ALL now out in Blood Advances. ClonoSEQ (NGS MRD) is superior to other MRD methods and should guide decisions about CAR T-cells or SCT MD Anderson Cancer Center #Leukemia doi.org/10.1182/blooda… #leusm

Measurable residual disease is a powerful predictor of clinical outcomes in acute lymphoblastic leukemia. ow.ly/Y2iM50VonWG #MRD #ALL #lymphoidneoplasia

WBC >70K (but not IKZF1plus) increases risk of relapse with blina+ponatinib in Ph+ ALL, particularly extramedullary/CNS. Pts with high WBC should be considered for systemic MTX/Ara-C and/or CAR T-cell consolidation jhoonline.biomedcentral.com/articles/10.11… #leusm #ALL